Oberland Capital

Biohaven is a clinical-stage biopharmaceutical company. It has a portfolio of late-stage product candidates targeting neurological diseases, including rare disorders. The company product candidates are based on multiple mechanisms-calcitonin gene-related peptide receptor antagonists, glutamate modulators and myeloperoxidase inhibitor. Its pipeline products include BHV3000-301, BHV3000-302, BHV3000-303, and others.

Verastem, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative treatments to enhance the survival and quality of life for cancer patients. The company markets COPIKTRA, an oral dual inhibitor of phosphoinositide 3-kinase (PI3K), which is approved for adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma and follicular lymphoma after previous therapies. Additionally, Verastem is advancing its pipeline with the focal adhesion kinase inhibitor defactinib, currently being studied in combination with immunotherapies for various cancers, including pancreatic and non-small cell lung cancer. The company focuses on targeting critical signaling pathways in cancer to inhibit tumor growth and promote cell death. Verastem has established collaborations with Yakult Honsha Co., Ltd. and CSPC Pharmaceutical Group Limited, and is headquartered in Needham, Massachusetts.

Verastem, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative treatments to enhance the survival and quality of life for cancer patients. The company markets COPIKTRA, an oral dual inhibitor of phosphoinositide 3-kinase (PI3K), which is approved for adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma and follicular lymphoma after previous therapies. Additionally, Verastem is advancing its pipeline with the focal adhesion kinase inhibitor defactinib, currently being studied in combination with immunotherapies for various cancers, including pancreatic and non-small cell lung cancer. The company focuses on targeting critical signaling pathways in cancer to inhibit tumor growth and promote cell death. Verastem has established collaborations with Yakult Honsha Co., Ltd. and CSPC Pharmaceutical Group Limited, and is headquartered in Needham, Massachusetts.

ImmunityBio, Inc. is an immunotherapy company focused on developing innovative treatments that enhance the body's immune response to combat various cancers without relying on high-dose chemotherapy. The company's product pipeline includes a memory T-cell cancer vaccine, albumin-linked chemotherapeutics, a novel IL-15 cytokine superagonist known as Anktiva, checkpoint inhibitors, and various vaccine therapies targeting specific tumor-associated antigens. Incorporated in 2014 and headquartered in El Segundo, California, ImmunityBio aims to address multiple tumor types, including bladder, lung, and colorectal cancers, as well as glioblastoma. The company is a subsidiary of NantWorks, LLC, and is actively engaged in clinical development to bring its next-generation immuno- and cellular therapies to market.

ImmunityBio, Inc. is an immunotherapy company focused on developing innovative treatments that enhance the body's immune response to combat various cancers without relying on high-dose chemotherapy. The company's product pipeline includes a memory T-cell cancer vaccine, albumin-linked chemotherapeutics, a novel IL-15 cytokine superagonist known as Anktiva, checkpoint inhibitors, and various vaccine therapies targeting specific tumor-associated antigens. Incorporated in 2014 and headquartered in El Segundo, California, ImmunityBio aims to address multiple tumor types, including bladder, lung, and colorectal cancers, as well as glioblastoma. The company is a subsidiary of NantWorks, LLC, and is actively engaged in clinical development to bring its next-generation immuno- and cellular therapies to market.

Zealand Pharma A/S is a biotechnology company based in Copenhagen, Denmark, specializing in the discovery and development of peptide-based medicines. The company has a growing proprietary pipeline that includes several clinical candidates such as glepaglutide for short bowel syndrome and dasiglucagon for diabetes management and congenital hyperinsulinism. Zealand's first developed medicine, lixisenatide, is a once-daily GLP-1 analogue for Type 2 diabetes, marketed globally outside the US. The company has established collaborations with major pharmaceutical partners, including Sanofi, Helsinn Healthcare, and Boehringer Ingelheim, enhancing its product offerings and expanding its reach in the market. Zealand Pharma is committed to advancing innovative therapies, with multiple projects in various stages of clinical development and preclinical research.

Centessa Pharmaceuticals is a clinical-stage biopharmaceutical company focused on innovating the drug development process through an asset-centric research and development model. The company manages a diverse portfolio of therapeutics across several therapeutic areas, including SerpinPC for Hemophilia A and B, LB101 for solid tumors, ORX750 for Narcolepsy Type 1 and other sleep disorders, and MGX292 for pulmonary arterial hypertension. Each therapeutic program is developed by a dedicated subsidiary, leveraging a centralized infrastructure and experienced management team to ensure efficient advancement of its pipeline assets.

Esperion discovers and develops pharmaceutical products for the treatment of cardiovascular and metabolic diseases. Esperion intends to commercialize a novel class of drugs that focuses on a new treatment approach called "HDL Therapy," which is based on the Company's understanding of high-density lipoprotein, or HDL, function.

Mirum Pharmaceuticals is a biopharmaceutical company dedicated to developing and commercializing therapies for serious liver diseases. Founded in 2018 and based in Foster City, California, the company focuses on addressing rare and orphan diseases. Its lead product candidate, maralixibat, is an investigational oral drug currently in Phase 3 clinical trials for treating progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome (ALGS), and biliary atresia. Additionally, Mirum is developing volixibat, aimed at treating intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. The company’s commitment to innovative therapies positions it as a key player in the biopharmaceutical landscape dedicated to improving the lives of patients with debilitating liver conditions.

Primmune Therapeutics, Inc. is a biotechnology company based in San Diego, California, focused on developing small molecule, orally administered toll-like receptor 7 (TLR7) agonists for cancer immunotherapy. Founded in 2017, the company aims to stimulate innate immunity to enhance the effectiveness of adaptive cancer treatments, such as checkpoint inhibitors. Its TLR7 agonist is designed to activate the immune system by producing cytokines and chemokines that boost cellular responses and facilitate the activation of natural killer cells. This approach enables healthcare providers to target metastatic diseases more effectively and promotes B-cell proliferation and activation, ultimately improving overall response rates and treatment durability for patients.

NorthStar Medical Radioisotopes, LLC, founded in 2006 and based in Madison, Wisconsin, develops technologies and raw materials for the nuclear medicine market in the United States. The company specializes in diagnostic and therapeutic radioisotopes, offering products such as Molybdenum-99 and Technetium-99m, which are essential for imaging in various medical fields including neurology, oncology, and cardiology. Additionally, NorthStar provides therapeutic isotopes like Actinium-225 and Bismuth-213 for treating incurable diseases such as cancers and HIV. The company has also created the RadioGenix System, an advanced radioisotope separation platform that produces Technetium-99m from non-uranium based Molybdenum-99. By addressing supply challenges in the medical isotope market, NorthStar aims to enhance patient care and support clinical research initiatives.

Impact Biomedicines, Inc. is a biotechnology company focused on the research, development, and commercialization of innovative treatments for patients with myeloproliferative neoplasms and various cancers. Founded in 2016 and based in San Diego, California, the company is primarily developing fedratinib, a potent and highly selective oral small molecule JAK2 kinase inhibitor. This drug is aimed at treating myelofibrosis and polycythemia vera, with potential applications for acute myeloid leukemia and colorectal cancer. Impact Biomedicines operates as a subsidiary of Bristol-Myers Squibb Company.

Melinta Therapeutics, Inc. is a commercial-stage pharmaceutical company based in Morristown, New Jersey, specializing in the discovery, development, and commercialization of anti-infective therapies for bacterial infections in North America. The company offers a range of antibiotics, including Baxdela, Vabomere, Orbactiv, and Minocin, targeting various serious bacterial infections such as acute bacterial skin and skin structure infections (ABSSSIs) and gram-negative infections. Melinta is actively advancing its investigational antibiotic, delafloxacin, which is currently in Phase 3 development for ABSSSIs. Additionally, the company is engaged in research to develop new classes of antibiotics aimed at combating drug-resistant pathogens, particularly the ESKAPE group responsible for many hospital-acquired infections. Through its innovative approaches, Melinta Therapeutics addresses the urgent need for new therapies against drug-resistant infections, a critical public health challenge today.

ClearPoint Neuro, Inc., established in 1998 and headquartered in Irvine, California, operates as a medical device company specializing in minimally invasive neurosurgical procedures guided by direct magnetic resonance imaging (MRI). The company's primary product is the ClearPoint system, designed for precise insertion of catheters, electrodes, and laser fibers to treat neurological conditions such as deep-brain stimulation and biopsy. Additionally, ClearPoint Neuro has product candidates like the ClearTrace system for cardiac applications, aiming to expand its offerings in MRI-guided procedures. The company collaborates with renowned institutions like Johns Hopkins University and Mayo Clinic to develop innovative therapies and has a strategic focus on improving patient outcomes through precise neurological interventions.

ClearPoint Neuro, Inc., established in 1998 and headquartered in Irvine, California, operates as a medical device company specializing in minimally invasive neurosurgical procedures guided by direct magnetic resonance imaging (MRI). The company's primary product is the ClearPoint system, designed for precise insertion of catheters, electrodes, and laser fibers to treat neurological conditions such as deep-brain stimulation and biopsy. Additionally, ClearPoint Neuro has product candidates like the ClearTrace system for cardiac applications, aiming to expand its offerings in MRI-guided procedures. The company collaborates with renowned institutions like Johns Hopkins University and Mayo Clinic to develop innovative therapies and has a strategic focus on improving patient outcomes through precise neurological interventions.